Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.
You may also be interested in...
Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010
Firm expects data from pivotal 24-week trials in mid-2010.
Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010
Firm expects data from pivotal 24-week trials in mid-2010.
Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
Vertex hopes to base Phase III trial design on 12-week dosing with telaprevir plus standard of care followed by standard of care for 12 weeks.